Sanofi to spin-out and launch European API manufacturer

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/NicoElNino)
(Image: Getty/NicoElNino)

Related tags Sanofi API API quality Coronavirus India China Europe

According to the French company, the spinout would enter the market as the second largest API producer globally.

In order to create the company, Sanofi will pool six of its existing European active pharmaceutical ingredient (API) production sites, alongside commercial and development capabilities.

The company stated that it expects the as-yet unnamed, standalone company to reach sales of €1bn ($1.08bn) by 2022, making it the second largest API producer, behind Lonza.

The new company would enter the market with 3,100 staff members, a headquarters in France and six facilities spread across Europe, located in Brindisi, Italy, Frankfurt, Germany, Haverhill, UK, St Aubin les Elbeuf, France, Újpest, Hungary, and Vertolaye, France.

In 2022, a planned initial public offering (IPO) would take place on the Euronext Paris – though it was noted that a decision would be made nearer the time, dependent on market conditions.

Sanofi is pitching the manufacturer as a means of “balancing the industry’s heavy reliance on API sourced from the Asian region,”​ the company said in a statement.

This position coincides with several high-profile cases of Asian-produced APIs being recalled due to impurities​, as well as the ongoing difficulties with supply due to the coronavirus​.

Philippe Luscan, EVP of Global Industrial Affairs at Sanofi, alluded to such issues in a statement: “Based on the expertise and experience built over decades within our industrial network, this new entity would help ensure a greater stability in supplying drugs to millions of patients in Europe and beyond.”

The independent company would enter the market with several advantages, such as possessing a long-term partnership with a company of the scale of Sanofi, being debt-free and possessing an existing network of customers.

Sanofi will take a minority stake of approximately 30% of the established company.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more